Clinical Research Directory
Browse clinical research sites, groups, and studies.
Swiss Dermatology Network of Targeted Therapies (SDNTT)
Sponsor: Swiss Dermatology Network for Targeted Therapies
Summary
The purpose of this study is to evaluate the long-term course of patients with psoriasis and psoriatic-arthritis in systemic treatments such as, methotrexate, cyclosporin A, fumaric acids, acitretin, systemic PUVA, etanercept, infliximab, adalimumab and ustekinumab. A patient will be included at first initiation of the treatment and will remain in the registry for 10 years, regardless of subsequent therapy. The registry will also evaluate safety clinical outcomes and health related quality of life.
Official title: Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1121
Start Date
2011-02
Completion Date
2032-03-15
Last Updated
2024-11-29
Healthy Volunteers
No
Conditions
Interventions
Adalimumab
all dosages, frequencies and durations prescribed
Etanercept
all dosages, frequencies and durations prescribed
Infliximab
all dosages, frequencies and durations prescribed
Ustekinumab
all dosages, frequencies and durations prescribed
Cyclosporine A
all dosages, frequencies and durations prescribed
Fumaric acids
all dosages, frequencies and durations prescribed
Methotrexate
all dosages, frequencies and durations prescribed
Other anti-psoriatic systemic treatments
all dosages, frequencies and durations prescribed
Locations (6)
Aarau Cantonal Hospital
Aarau, Switzerland
Basel University Hospital
Basel, Switzerland
Inselspital - Bern University Hospital
Bern, Switzerland
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland
St. Gallen Cantonal Hospital
Sankt Gallen, Switzerland
Zurich University Hospital
Zurich, Switzerland